|
Crohn Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Drug regimens applied in the year before index hospitalization were as follows: no IBD drugs (43.6% ulcerative colitis, 43.1% Crohn's disease); 5-ASA (45.7% ulcerative colitis, 19.1% Crohn's disease); local steroids (17.9% ulcerative colitis, 17.6% Crohn's disease); systemic steroids (38.6% ulcerative colitis, 29.4% Crohn's disease); immunomodulators (10.7% ulcerative colitis, 18.1% Crohn's disease); biologics (10% ulcerative colitis, 24% Crohn's disease); and calcineurin inhibitors (2.1% ulcerative colitis, 1.5% Crohn's disease).
|
31834046 |
2020 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, 5-ASA was more effective than placebo in both induction and maintenance treatment of UC, but there were conflicting results on the effect of 5-ASA on the induction treatment or relapse of CD.
|
30844556 |
2019 |
|
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In our study, we characterized the anti-inflammatory activity of mesalazine (5-ASA) and chlorogenic acid (CGA) encapsulated in liposomal formulation in the animal model of CD.
|
31443089 |
2019 |
|
Crohn Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
More importantly, there may be a potential association of the different genotypes of rs17525495 with the treatment efficacy of 5-ASA and glucocorticoids in patients with Crohn's disease.
|
31093505 |
2019 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abbreviations: ADA: Adalimumab; CD: Crohn disease; ECCO: European Crohn's and Colitis Organisation; EEN: exclusive enteral nutrition; ESPGHAN: European Society for Paediatric Gastroenterology Hepatology and Nutrition; FMT: faecal microbiota transplantation; GDP: gross domestic product; HIC: high-income countries; IBD: inflammatory bowel disease; IBDU: inflammatory bowel disease unclassified; IC: ileocolonoscopy; IFX: infliximab; IPAA: ileal pouch anal anastomosis; LMIC: low- and middle-income countries; MH: mucosal healing; OGD: oesophago-gastroduodenoscopy; PCDAI: Paediatric Crohn's Disease Activity Index; PIBD: paediatric inflammatory bowel disease; PUCAI: Paediatric Ulcerative Colitis Activity Index; UC: ulcerative colitis; UGIT: upper gastrointestinal tract; VEO-IBD: very early-onset IBD; WLE: white light endoscopy; 5-ASA: 5 aminosalicylic acid; 6-MP: 6-mercaptopurine.
|
30900526 |
2019 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The experimental data revealed that the synthesized terpolymeric semi-IPN hydrogel may have useful biomedical applications, especially as a carrier of protein (BSA), or 5-ASA (a therapeutic option for conditions of the colon such as Crohn's Disease and Ulcerative Colitis).
|
30813044 |
2019 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
For induction of clinical remission, four meta-analyses were selected (AZA and 6-MP showed no advantage over placebo, MTX or 5-ASA in CD; MTX showed no statistically significant difference versus placebo, 6-MP, or 5-ASA in UC; tacrolimus was superior to placebo for UC in two meta-analyses).
|
30863001 |
2019 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Randomised controlled trials (RCTs) that included participants with CD in remission following surgery and compared 5-ASAs to no treatment, placebo or any other active intervention with duration of at least three months were considered for inclusion.
|
31220875 |
2019 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This contrasts a small decrease in immunomodulator and 5-ASA use for CD and relative constancy of other classes including corticosteroids-only use as primary IBD medication from 2007 to 2015.
|
29164650 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is a lack of confidence in published clinical trials, and a desire for more robust evidence to inform 5-ASA use in CD.
|
29959726 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although immunomodulators are increasingly used in Crohn's disease (CD), a significant number of gastroenterologists still use 5-aminosalicylate (5-ASA) in combination with azathioprine (AZA) or 6-mercaptopurine (6-MP); there is limited evidence regarding the benefit of concomitant 5-ASA with AZA/6-MP compared with AZA/6-MP monotherapy for the treatment of CD.
|
29576767 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
These SF membranes with core-shell structure and functional encapsulation of CUR and 5-ASA should be useful for further studies toward the treatment of CD.
|
29411947 |
2018 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to systematically review the literature and update evidence concerning effects of 5-ASA on the risk of colorectal cancer (CRC) and dysplasia (Dys) in patients with ulcerative colitis (UC) or Crohn's disease (CD).
|
27906680 |
2017 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Discrepancies between guidelines and management were found in: 25/80 (31%) of patients with UC in remission receiving oral 5-aminosalicyclates (5-ASAs) as maintenance therapy, and; 46/110 (42%) of patients with small bowel and/or ileo-cecal CD receiving 5-ASA.
|
28128675 |
2017 |
|
Crohn Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Concentrations of thioguanine nucleotides (TGN) and methymercaptopurine nucleotides (MMPN), metabolites of thiopurines, were measured by high performance liquid chromatography in 12 young patients (3 females and 9 males, median age 16 years) with inflammatory bowel disease (6 Crohn's disease and 6 ulcerative colitis) treated with thiopurines (7 mercaptopurine and 5 azathioprine) and 5-ASA.
|
25834322 |
2015 |